Opioid-free Anesthesia With a Mixture of Dexmedetomidine-lidocaine-ketamine
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04858711 |
|
Recruitment Status :
Recruiting
First Posted : April 26, 2021
Last Update Posted : October 19, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pain, Postoperative Pain, Acute Pain, Chronic Pain, Neuropathic Pain, Nociceptive Ketamine Dexmedetomidine Lidocaine Central Nervous System Depressants Analgesia Analgesics Analgesics Non-narcotic | Drug: ketamine-lidocaine-dexmedetomidine Drug: fentanyl | Not Applicable |
Inadequately treated postoperative pain after gynecological surgery may untowardly affect early recovery and also lead to the development of chronic pain. Laparoscopic surgery is associated with diminished postoperative pain but this does not mean that patients subjected to laparoscopic operations are not in need for analgesia intra- and postoperatively. Opioid-based analgesia is associated with side-effects, such as respiratory depression, postoperative nausea and vomiting and occasional induction of tolerance and hyperalgesia. Therefore, in recent years research has focused on the quest for non-opioid-based regimens for perioperative analgesia in the context of multimodal analgesic techniques. These techniques have been shown to possess significant advantages, such as allowing earlier mobilization after surgery, early resumption of enteral feeding and reduced hospital length of stay.
In this context, the intraoperative intravenous injection of lidocaine has been reported to improve postoperative pain control, reduce opioid consumption and improve the quality of postoperative functional recovery after general anesthesia. Intraoperative infusions of ketamine (an N-methyl-D-aspartate receptor inhibitor) have also been correlated with reduced pain scores and a decrease in analgesic requirements postoperatively. Lastly, dexmedetomidine is a highly selective alfa-2 adreno-ceptor agonist that provides sedation, analgesia, and sympatholysis. Its perioperative intravenous administration has been associated with a reduction in postoperative pain intensity, analgesic consumption and nausea.
There is insufficient data in literature investigating the effect of combinations of these agents intraoperatively. It would be of interest to demonstrate whether the administration of combinations can be used towards the achievement of a completely opioid-free anesthetic regimen. Additionally, it can be hypothesized that the combination of non-opioid drugs with different targets can lead to enhanced postoperative recovery, an improved opioid-sparing effect and a decrease in the development of chronic pain as compared to the administration of opioids.
Therefore, the aim of this study will be to investigate the effect of a combination of intravenous infusions of lidocaine-ketamine-dexmedetomidine versus fentanyl on recovery profile, quality of recovery and postoperative pain after elective laparoscopic gynecological surgery.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | The Effect of a Mixture of Dexmedetomidine-lidocaine-ketamine in One Syringe Versus Opioids on Recovery Profile and Postoperative Pain After Gynecological Laparoscopic Surgery |
| Actual Study Start Date : | April 1, 2021 |
| Estimated Primary Completion Date : | April 30, 2023 |
| Estimated Study Completion Date : | April 30, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: ketamine-lidocaine-dexmedetomidine (KLD) group
combination of ketamine-lidocaine-dexmedetomidine in one syringe
|
Drug: ketamine-lidocaine-dexmedetomidine
In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
Other Name: KLD group |
|
Active Comparator: fentanyl (control) group
syringe of fentanyl
|
Drug: fentanyl
In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
Other Name: Control group |
- change from baseline in Quality of Recovery (QoR)-15 score after surgery [ Time Frame: 24 hours postoperatively ]The QoR-15 is a quality of recovery scale that consists of 15 questions (items),including questions regarding pain (2 items), physical comfort (5 items), self-care ability (2 items), psychological support (2 items) and emotional state (4 items). Every item is scored on a scale of 10, with the lowest total score of 0 and the highest score of 150. The higher the score, the better the recovery quality of the patient
- pain score on arrival to Post-Anesthesia Care Unit (PACU) [ Time Frame: immediately postoperatively ]pain score by the use of Numeric Rating Scale (NRS) on arrival to PACU, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
- pain score at discharge from Post-Anesthesia Care Unit (PACU) [ Time Frame: at discharge from Post Anesthesia Care Unit (PACU), approximately 1 hour postoperatively ]pain score by the use of Numeric Rating Scale (NRS) at discharge from PACU, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
- pain score 3 hours postoperatively [ Time Frame: 3 hours postoperatively ]pain score by the use of Numeric Rating Scale (NRS) 3 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
- pain score 6 hours postoperatively [ Time Frame: 6 hours postoperatively ]pain score by the use of Numeric Rating Scale (NRS) 6 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
- pain score 24 hours postoperatively [ Time Frame: 24 hours postoperatively ]pain score by the use of Numeric Rating Scale (NRS) 24 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
- Post Anesthesia Care Unit (PACU) duration of stay [ Time Frame: immediately postoperatively ]duration of patient stay at PACU
- sedation on arrival to Post-Anesthesia Care Unit [ Time Frame: immediately postoperatively ]sedation will be assessed with a 5-point sedation scale, where: 1, patient perfectly conscious; 2, patient feels a little drowsy; 3, patient seems to be sleeping but immediately reacts to verbal stimulation; 4, patient seems to be sleeping but slowly reacts to verbal stimulation and 5, patient seems to be sleeping and does not react to verbal stimulation but does react to a stimulus such as shaking or pain
- sedation at discharge from Post-Anesthesia Care (PACU) Unit [ Time Frame: at discharge from Post Anesthesia Care Unit (PACU), approximately 1 hour postoperatively ]sedation will be assessed with a 5-point sedation scale, where: 1, patient perfectly conscious; 2, patient feels a little drowsy; 3, patient seems to be sleeping but immediately reacts to verbal stimulation; 4, patient seems to be sleeping but slowly reacts to verbal stimulation and 5, patient seems to be sleeping and does not react to verbal stimulation but does react to a stimulus such as shaking or pain
- sevoflurane consumption during general anesthesia [ Time Frame: change of sevoflurane vaporizer weight from before induction to end of anesthesia, an average period of 2-3 hours ]the sevoflurane vaporizer will be weighed before anesthetic induction and at the end of anesthesia and consequently sevoflurane consumption during anesthesia will be determined
- time to first request for analgesia [ Time Frame: during stay in Post-Anesthesia Care Unit (PACU), approximately 1 hour postoperatively ]the time for the first patient request for analgesia will be noted
- morphine consumption in Post-Anesthesia Care Unit (PACU) [ Time Frame: immediately postoperatively ]mg of morphine requested during patient PACU stay
- tramadol consumption in the first 48 hours [ Time Frame: 48 hours postoperatively ]patients will be followed for cumulative tramadol consumption for 48 hours postoperatively
- sleep quality [ Time Frame: 24 hours postoperatively ]subjective evaluation of sleep quality by patients, based on a sleep questionnaire (evaluation of sleep duration, number of nocturnal awakenings and marking of sleep quality)
- first mobilization after surgery [ Time Frame: 24 hours postoperatively ]patients will be questioned regarding the time at which they mobilized after surgery
- gastrointestinal recovery after surgery [ Time Frame: 24 hours postoperatively ]patients will be questioned regarding the time they first felt enteral sounds and the time they had their first flatus after surgery
- satisfaction from postoperative analgesia [ Time Frame: 24 hours postoperatively ]satisfaction from postoperative analgesia on a six-point Likert scale with 1 marked as minimal satisfaction and 6 as maximal satisfaction
- first fluid intake [ Time Frame: 24 hours postoperatively ]patients will be questioned regarding the time they had their first fluid intake
- first solid intake [ Time Frame: 24 hours postoperatively ]patients will be questioned regarding the time they had their first solid intake
- hospitalization time [ Time Frame: 96 hours postoperatively ]duration of hospital stay after surgery in hours
- fentanyl requirement during surgery [ Time Frame: intraoperatively ]dose of required fentanyl intraoperatively to maintain systolic arterial blood pressure and heart rate within the 20% of baseline value
- side effects intraoperatively [ Time Frame: intraoperatively ]patients will be monitored for side-effects of the administered agents intraoperatively
- side effects postoperatively [ Time Frame: 48 hours postoperatively ]patients will be monitored for side-effects of the administered agents postoperatively
- incidence of chronic pain 1 month after surgery [ Time Frame: 1 month after surgery ]occurrence of chronic pain at the site of the operation 1 month after surgery, with the use of the Numeric Rating Scale (NRS), at rest and during movement
- incidence of chronic pain 3 months after surgery [ Time Frame: 3 months after surgery ]occurrence of chronic pain at the site of the operation 3 months after surgery, with the use of the Numeric Rating Scale (NRS), at rest and during movement
- time to emergence [ Time Frame: up to 2-3 hours after start of surgery ]time from sevoflurane discontinuation to first patient response (eye opening)
- time to extubation [ Time Frame: up to 2-3 hours after start of surgery ]time from sevoflurane discontinuation to tracheal extubation
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- adult female patients
- American Society of Anesthesiologists (ASA) classification I-II
- elective laparoscopic gynecological surgery
Exclusion Criteria:
- body mass index (BMI) >35 kg/m2
- contraindications to local anesthetic administration or non-steroidal agents administration
- systematic use of analgesic agents preoperatively
- chronic pain syndromes preoperatively
- neurological or psychiatric disease on treatment
- pregnancy
- severe hepatic or renal disease
- history of cardiovascular diseases/ arrhythmias/ conduction abnormalities
- bradycardia(<55 beats/minute)
- drug or alcohol abuse
- language or communication barriers lack of informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04858711
| Contact: Kassiani Theodoraki, PhD, DESA | +306974634162 | ktheodoraki@hotmail.com | |
| Contact: Sofia Apostolidou, MD | sofia.apos@hotmail.com |
| Greece | |
| Aretaieion University Hospital | Recruiting |
| Athens, Greece, 115 28 | |
| Contact: Kassiani Theodoraki, PhD, DESA #306974634162 ktheodoraki@hotmail.com | |
| Principal Investigator: | Kassiani Theodoraki, phD, DESA | Aretaieion University Hospital |
| Responsible Party: | Dr Kassiani Theodoraki, Professor of Anesthesiology, Aretaieion University Hospital |
| ClinicalTrials.gov Identifier: | NCT04858711 |
| Other Study ID Numbers: |
306/26-03-2021 |
| First Posted: | April 26, 2021 Key Record Dates |
| Last Update Posted: | October 19, 2021 |
| Last Verified: | October 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Neuralgia Pain, Postoperative Acute Pain Chronic Pain Nociceptive Pain Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases Lidocaine Fentanyl Dexmedetomidine |
Ketamine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Anti-Arrhythmia Agents Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Hypnotics and Sedatives Analgesics, Non-Narcotic Analgesics |